Abstract: This invention provides a single phase silicone acrylate formulation that resists phase separation and includes (A) at least one of a silicone, an acrylate, and combinations thereof. The single phase silicone acrylate formulation also includes (B) a silicone acrylate hybrid compatibilizing agent including silicone functionality and (meth)acrylate functionality and that is the reaction product of a silicon-containing pressure sensitive adhesive composition, a (meth)acrylate, and an initiator. A method of minimizing phase separation of the single phase silicone acrylate formulation includes the step of combining (A) and (B) to form the single phase silicone acrylate formulation.

Abstract: This invention relates to matrix patches for the topical (i.e., transdermal) delivery of piroxicam and methods for the treatment of acute and chronic pain and inflammation therewith, particularly pain and inflammation caused by sports injuries or other muscle aches or injuries requiring the application of analgesic and/or anti-inflammation medication, in this instance, piroxicam.

Abstract: The present invention relates to nonaqueous preparation for percutaneous absorption prepared by laminating an adhesive layer comprising a nonsteroidal anti-inflammatory analgesic in an alkali metal salt form, and an inorganic acid which is strongly acidic compared with the nonsteroidal anti-inflammatory analgesic in a free form, together with a nonaqueous base, on a support. According to the present invention, drug-releasing characteristics and skin penetration in a nonaqueous preparation for percutaneous absorption can be improved because the addition of an inorganic acid in a nonaqueous base containing a drug in an alkali metal salt form leads to an improvement in the solubility of the drug in the base, and a good partitioning of the drug to skin surface. In addition, as the inorganic acid has no alcoholic hydroxy group in the structure, the inorganic acid does not react with the drug, therefore it causes no lowering in the stability of the drug by esterification.

Abstract: An adhesive formulation is provided for use in a film wound dressing. The adhesive formulation includes a medical-grade adhesive and an antimicrobial substance. This adhesive formulation may be coated onto one or more surfaces of a medical-grade transparent film suitable for a wound dressing. The antimicrobial material may be a silane quaternary ammonium salt. The silane quaternary ammonium salt may comprise 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride. The 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride may constitute about 72% of the silane quaternary ammonium salt. The medical-grade adhesive may comprise an acrylic adhesive. Further, the adhesive formulation may include about 0.01% to about 60% of the antimicrobial substance. The transparent film dressing may further include a release liner applied over the coated side(s) of the transparent film. The transparent film may comprise polyurethane.

Abstract: Devices for administration of one or more active agents to the skin or mucosa of a host are formed in the nature of a double-disk patch. One outer layer functions as the primary adhesive layer for adhering the patch to the host. The other inner layer contains at least one active agent to be administered to the host. The inner layer is bonded to the outer layer through an opening provided in an interposed active agent impermeable release layer. The release layer separates a circumferential portion of the active agent containing inner layer from the outer adhesive layer to inhibit migration of the active agent therebetween.

Abstract: A transdermal absorption preparation having a support and a pressure-sensitive adhesive layer consisting of multiple layers, wherein the pressure-sensitive adhesive layer comprises a drug-retaining layer containing a drug and an acrylic pressure-sensitive adhesive and a skin adhesion layer containing a styrene-isoprene-styrene block copolymer. This preparation can continuously release bisoprolol at a constant concentration. Moreover, it can be easily produced.

Abstract: There is disclosed various devices and articles comprising phosphors for converting electromagnetic energy to radiation having a shorter wavelength, the composition comprising at least one phosphor capable of converting an initial electromagnetic radiation having a wavelength (A) to an electromagnetic radiation having a shorter wavelength (B) comprising UV radiation or radiation of a shorter wavelength. There is also a method of sterilizing such devices and articles by exposing it to UV radiation or radiation of a shorter wavelength for a time sufficient to deactivate or kill at least one microorganism and/or for a time sufficient to inhibit abnormal cell growth within the body, when the composition is in an implantable medical device.

Abstract: The present invention provides a production method of a nicotine transdermal preparation, which is capable of producing a nicotine transdermal preparation conveniently and economically, while maintaining highly precise content uniformity, which is capable of producing a preparation simultaneously achieving fixedness and a soft feeling during adhesion, associated with reduced skin irritation upon peeling off and superior in adhesive property. The present invention provides a nicotine transdermal preparation superior in content uniformity, simultaneously achieving fixedness and a soft feeling during adhesion, and showing reduced skin irritation upon peeling off.

Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.

Abstract: An external patch capable of stable prolonged release and transdermal absorption of active ingredient hormones (estrogens and/or progestogens) contained in a pressure sensitive adhesive layer, which external patch ensures low irritation on the skin. In particular, an external patch comprising a support and, superimposed thereon, a pressure sensitive adhesive layer, characterized in that the pressure sensitive adhesive layer comprises, as indispensable components, 5 to 50 wt. % of styrene/isoprene/styrene block copolymer, 20 to 70 wt. % of tackifier resin, 10 to 60 wt. % of softener and 1 to 20 wt. % of polyvinylpyrrolidone and contains, as an active ingredient, estrogen and/or progestogen.

Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.

Abstract: Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked compositions include preventing adhesions following surgery or injury, and preventing scar tissue formation.

Abstract: The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

Abstract: Topical patch preparations that contain an odorless physiological cooling agent, and methods for using the same are provided. The subject topical patch preparations are made up of an adhesive gel composition that is present on a support, where the adhesive gel composition includes the odorless physiological cooling agent, a water-soluble polymer gel, water and a water holding agent. In using the subject topical patch preparations, the topical patch preparations are applied to a skin surface of a subject and maintained at the site of application for a period of time sufficient for an effective amount of the an odorless physiological cooling agent to be administered to the subject. The subject invention finds use in a variety of applications.

Abstract: A process for the preparation of a bioadhesive laminate comprising a hot-melt extruded reservoir layer and a hot-melt extruded backing layer is provided. The reservoir layer comprises a thermoplastic bioadhesive composition containing an active agent. An active agent-containing thermoplastic bioadhesive hydrophilic composition is hot-melt coextruded with a hydrophobic composition to form at least a bi-layered laminate. The hydrophilic composition and the hydrophobic composition have at least one polymer in common. In addition, the melt flow index of the hydrophobic composition is within 50% of the melt flow index of the hydrophilic composition. As a result, the laminate has a uniform transverse cross-section and/or a uniform longitudinal cross-section throughout a major of the length of the laminate. Moreover, when the laminate is divided into unit doses of approximately the same size, they have a high degree of content uniformity with respect to the active agent(s) present therein.

Abstract: The invention relates to a dermal application system for aminolevulinic acid-derivatives, i.e. a pressure-sensitive matrix system containing a crystalline aminolevulinic acid derivative.

Abstract: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.

Abstract: The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient.

Abstract: The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

Abstract: A therapeutic device includes a fluid mover for one of raising, compressing, or transferring fluid, a therapeutic member operably connected to the fluid mover and actuated thereby, the therapeutic member operably disposably used on a patient in a manner to deliver therapy to the patient as function of actuation of the fluid mover, a controller operably associated with the fluid mover for controlling operation thereof, and a leak, blockage, temperature, voltage or current sensor operably connected to the fluid mover and the controller and to sense a leak, blockage, temperature, voltage or current in the device and send a signal to the controller whereby the controller controls the fluid mover as a function of the sensed signal.

Abstract: A dermal or transdermal therapeutic system comprising a reservoir that contains at least one active substance, an active substance-permeable membrane which delimits the active-substance reservoir, and a closing layer. The closing layer is impermeable to the active substance at a temperature lying below the skin temperature while being permeable at skin temperature and above.

Abstract: The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient.

Abstract: A transdermally absorbable preparation that even when a drug with poor solubility in a base is added in high concentration, is stable over time and can suppress crystallization of the drug, excelling in transdermal absorbability. There is provided a transdermally absorbable preparation, comprising a base and, added thereto, at least composite particles which are composed of a silicate compound and an organic acid and a drug.

Abstract: The present invention provides a transdermal drug delivery system comprising a drug-containing matrix layer comprising: (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; and (b) an acrylate-rubber hybrid as an adhesive.

Abstract: A patch formulation for external use where a basic drug, an organic acid and an organic acid salt are combined as essential components is disclosed. The basic drug is preferably in the form of its acid addition salt. The organic acid is preferably a carboxylic acid having carbon atoms of 2 to 7, and more preferably at least one acid selected from the group consisting of acetic, lactic, tartaric, citric, malic, benzoic and salicylic acids. The organic acid salt is preferably a metal salt of a carboxylic acid, and more preferably sodium acetate.

Abstract: The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.

Abstract: Methods for producing silver-bonded antimicrobial moist wound dressings include adding a silver-containing compound to a 0.1-30% aqueous solution of an alkaline solvent to dissociate silver ions from the silver-containing compound; dissolving CMC in water or an organic solvent to obtain a CMC solution; mixing the silver ion-containing solution with the CMC solution so that the hydrogen ions (H+) of the hydroxyl groups of the CMC are replaced by the silver ions to prepare a silver-CMC compound; dispersing and absorbing the silver-CMC compound in a medium; and drying the medium.

Abstract: A stable percutaneous absorption-type pharmaceutical preparation for percutaneous administration of drugs except for selegiline and selegiline hydrochloride, which does not suffer a decrease in the cohesive force of the adhesive layer therein even in the presence of sweat components due to perspiration during wear and which is free from cohesive failure and resultant adhesive remaining when stripped off. A percutaneous absorption-type pharmaceutical preparation which comprises: a support; and an adhesive layer containing an adhesive, a metal chloride and a percutaneously-absorptive drug except for selegiline and selegiline hydrochloride, wherein the adhesive layer is subjected to a crosslinking treatment.

Abstract: An adhesive patch configured to attach an ostomy appliance to a patient includes a peripheral rim disposed around a central hole that is attachable to a stoma of the patient; and a band of adhesive extending from the peripheral rim to an inner border of the adhesive patch and having a pattern of curvilinear indentations extending to the peripheral rim of the patch.

Abstract: A getter system (20) is provided for the sorption of organic molecules on the inside of active systems (30) for the transdermal release of drugs. The getter system is suitable to avoid the corrosion of electrical parts of these systems, caused by these organic molecules in the presence of water.

Abstract: The present invention provides an adhesive material to be adhered to the skin etc., which maintains, for a certain time period after adhesion thereof to the skin surface, suitable adhesiveness that does not allow easy peeling or cause irritation to the skin, and which permits, when it is to be peeled off from the skin surface after the lapse of a desired certain time period, easy peeling without causing pain or physical irritation, and an adhesive preparation containing the adhesive material and a percutaneously absorbable drug in the adhesive layer. Specifically, the present invention provides an adhesive material containing a support and an adhesive layer laminated on one surface of the support, wherein the adhesive layer has an apparent viscosity at 30° C. of 0.2×104 to 10×104 Pa·s and comprises two kinds of synthetic rubbers having different flowability.

Abstract: A composition for production of a crosslinkable pressure-sensitive adhesive for skin, obtained by dissolving in a solvent 100 parts by weight of an acrylic copolymer (copolymer A) comprising a (meth)acrylic acid alkyl ester as the main constituent component and 3-45 wt % diacetoneacrylamide as an essential constituent component, and containing no free carboxyl groups, and 0.1-30 parts by weight of an acrylic copolymer (copolymer B) comprising a (meth)acrylic acid alkyl ester as the main constituent component and a primary amino group and/or carboxyhydrazide group on a side chain, and containing no free carboxyl groups.

Abstract: Disclosed is an adhesive skin patch having an SIS block copolymer as an adhesive component, which has an improved handling property and can reduce irritation to a user. The adhesive skin patch comprises a flexible substrate and an adhesive layer laminated on the substrate, wherein the adhesive layer comprises a styrene-isoprene-styrene block copolymer. In the adhesive skin patch, the tan ? value of the adhesive agent as determined by measuring a dynamic viscoelasticity at 32° C. satisfies a requirement represented by the following formula 1 at at least one frequency laying between 0.04 to 0.25 Hz. 0.25x+0.05?y?0.25x+0.10 (formula 1) [wherein x represents a frequency (Hz); and y represents a tan ? value.

Abstract: A polyacrylate formulation suitable for delivery of drug through a body surface of an individual. By loading the drug and permeation enhancers at a high concentration into a polyacrylate proadhesive that has inadequate adhesive properties for typical adhesive application on the skin, a formulation with desirable adhesive characteristics and effective therapeutic properties can be made. The proadhesive has higher glass transition temperature than typical pressure sensitive adhesives.

Abstract: A tissue treatment apparatus and method are provided for treating tissue by the application of the time-varying sub-atmospheric pressure. The apparatus includes a cover adapted to cover a wound and adapted to maintain sub-atmospheric pressure the site of the wound. The apparatus further includes a source of suction configured to generate a time-varying sub-atmospheric pressure having a periodic waveform comprising a gradual change in pressure. The suction source cooperates with the cover to supply the time-varying sub-atmospheric pressure under the cover to the wound. The time-varying sub-atmospheric pressure may vary between a first pressure value below the inherent tissue tension of the wound tissue and a second pressure value above the inherent tissue tension of the wound tissue.

Abstract: The patch according to an embodiment of the present invention includes: a support; and a pressure-sensitive adhesive layer on at least one surface of the support, wherein: the pressure-sensitive adhesive layer contains an acrylic copolymer obtained by copolymerizing monomer components containing (a) at least one kind of a monomer of a (meth)acrylic acid alkyl ester and (b) at least one kind of a monomer of an N-hydroxyalkyl(meth)acrylamide; a content of the (meth)acrylic acid alkyl ester monomer (a) with respect to a total amount of the monomer components is 50 wt % to 90 wt % and a content of the N-hydroxyalkyl(meth)acrylamide monomer (b) with respect to the total amount is 1 wt % to 20 wt %; and the monomer components are substantially free of a monomer having a carboxyl group.

Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.

Abstract: It is intended to provide a preparation for percutaneous administration of 2-(4-ethyl-1-piperazinyl)-4-(4-fluoro-phenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine (Compound A), which inhibits the generation of a metabolite and is capable of continuously maintaining a blood drug level. Specifically, a tape preparation comprising an adhesive layer formed on one surface of a support, characterized in that the adhesive layer contains (1) Compound A or a physiologically acceptable acid addition salt thereof, and (2) an acrylic adhesive, or (1) Compound A or a physiologically acceptable acid addition salt thereof, (2) an acrylic adhesive, and (3) a permeation enhancer is provided.

Abstract: A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin.

Abstract: A transdermal composition is disclosed which contains a blend of one or more polymers, one or more drugs, at least one of which has a low molecular weight and is liquid at or about room temperatures. The composition is substantially free of water and liquids which have a normal boiling point (a) optionally below processing temperatures and (b) greater than or equal to the temperature of the low molecular weight drugs. The composition does not suffer from the substantial loss of the lower molecular weight drug during production of the transdermal system. A transdermal composition is also disclosed which has one or more drugs, at least one of which has a low molecular weight and is liquid at or about room temperatures, and a polymer matrix including one or more high shear resistant polymers. The high shear resistant polymer(s) reduce the plasticizing effect of the low molecular weight drug, and has sufficient tack and shear for application to a human being.

Abstract: Disclosed are bupivacaine transdermal delivery systems, and related methods.

Abstract: A transdermal drug delivery device is shown and described. The device includes an occlusive or non-occlusive backing, an adhesive, at least one drug delivery region, an adhesive, and a release liner. The device has an open configuration and a closed configuration. When the device is in the closed configuration, the adhesive, the at least one drug delivery region, and the release liner are disposed between first and second portions of the backing.

Abstract: The invention relates to a TTS with backing layers that guarantee a high wear comfort and that facilitate application in regions of the human body that are subject to great mechanical loads, especially the large joints of the extremities. The inventive backing layers overcome the disadvantages with respect to reduced absorption of the active substance by the skin that are typically associated with such backing layers. The inventive systems are preferably used for the local of systemic administration of anti-inflammatory and pain-relieving active substances.

Abstract: The present invention aims at providing an adhesive preparation wherein a drug is sufficiently dissolved in an adhesive layer and is not easily separated from the adhesive layer even during preservation of the adhesive preparation. The present invention provides an adhesive preparation having an adhesive layer on at least one surface of a support, wherein the adhesive layer comprises a first synthetic rubber having a viscosity average molecular weight of 1,600,000-6,500,000, a drug, an organic liquid component and a tackifier. The present invention further provides the aforementioned adhesive preparation, wherein the organic liquid component is contained in the adhesive layer in a proportion of 20 wt % or above relative to the total weight of the adhesive layer.

Abstract: A transdermal therapeutic system for administering lipophilic, poorly water-soluble and/or sparingly skin-permeable pharmaceutical active substances. The active substance is present in a multi-component enhancer system consisting of 4 components and each component of the multi-component enhancer system is selected from a different one of the substance groups: a) terpenes, b) cyclic glucitol ethers, c) medium-chain triglycerides of capric and caprylic acid and/or of linoleic acid; and d) longer-chain alcohols having a chain length of 8 or more carbon atoms.

Abstract: A medical patch system has a first medical patch including an outer locating ring securable to a surface and an inner patch, separable from the outer locating ring, disposed within the outer locating ring. The medical patch system includes a second medical patch adapted for insertion into the central area bounded by the outer locating ring after the inner patch is separated from the outer locating ring. The second medical patch includes a second outer locating ring securable to the surface, and a second inner patch section, separable from the second outer locating ring, disposed within a second central area bounded by the second outer locating ring. The first and second outer locating rings have adhesive layers for securing the outer locating rings to a surface. The adhesive layers on the respective outer locating rings have different sizes, shapes or patterns to minimize skin irritation.

Abstract: In the adhesive pharmaceutical preparation of the invention containing bisoprolol, a pressure-sensitive adhesive layer is laminated on one side of the backing. The pressure-sensitive adhesive layer contains a branched monoalcohol having from 12 to 28 carbon atoms, a free base of bisoprolol and a polyisobutylene pressure-sensitive adhesive. Accordingly, compatibility of the polyisobutylene pressure-sensitive adhesive with the free base of bisoprolol can be specifically increased. As a result, not only it becomes possible to increase blending amount of the free base of bisoprolol but also bleed of the free base of bisoprolol from the pressure-sensitive adhesive layer can be suppressed and, what is more, the pressure-sensitive adhesion characteristics sufficient from the practical point of view can be obtained.

Abstract: A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.

Abstract: A method for preparing hydrophilic pressure sensitive adhesive (PSA) compositions is provided, wherein the method enables preparation of adhesives having a particular, optimized degree of adhesion. That is, the hydrophilic PSA is comprised of a hydrophilic polymer and a complementary short-chain plasticizing agent, wherein the hydrophilic polymer and plasticizing agent are capable of hydrogen bonding or electrostatic bonding to each other and are present in a ratio that optimizes key characteristics of the adhesive composition, such as adhesive strength, cohesive strength and hydrophilicity. The adhesive is useful in a wide variety of contexts, e.g., as a biomedical adhesive for application to the skin or other body surface, and as such finds utility in the areas of drug delivery systems (e.g., topical, transdermal, transmucosal, iontophoretic), medical skin coverings and wound healing products and biomedical electrodes.